Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
8 May 24
8-K
Tango Therapeutics Reports First Quarter 2024 Financial Results
8 May 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
PRE 14A
Preliminary proxy
17 Apr 24
S-8
Registration of securities for employees
18 Mar 24
10-K
2023 FY
Annual report
18 Mar 24
8-K
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
18 Mar 24
8-K
Results of Operations and Financial Condition
7 Feb 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Tango Therapeutics Reports Third Quarter 2023 Financial Results
8 Nov 23
EFFECT
Notice of effectiveness
12 Sep 23
CORRESP
Correspondence with SEC
7 Sep 23
UPLOAD
Letter from SEC
7 Sep 23
S-3
Shelf registration
1 Sep 23
8-K
Departure of Directors or Certain Officers
30 Aug 23
D
$80.02 mm in equity / options, sold $80.02 mm, 17 investors
24 Aug 23
8-K
Tango Therapeutics Announces $80 million Private Placement Financing
10 Aug 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
8-K
Tango Therapeutics Reports Second Quarter 2023 Financial Results
7 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
7 Jun 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Tango Therapeutics Reports First Quarter 2023 Financial Results
9 May 23
ARS
2022 FY
Annual report to shareholders
24 Apr 23
DEFA14A
Additional proxy soliciting materials
24 Apr 23
DEF 14A
Definitive proxy
24 Apr 23
10-K
2022 FY
Annual report
27 Mar 23
8-K
Tango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
27 Mar 23
8-K
Tango Therapeutics Announces Appointment of Adam Crystal, M.D., Ph.D. as President of Research and Development
28 Feb 23
S-8
Registration of securities for employees
7 Feb 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Tango Therapeutics Reports Third Quarter 2022 Financial Results
10 Nov 22
EFFECT
Notice of effectiveness
29 Sep 22
POS AM
Prospectus update (post-effective amendment)
21 Sep 22
EFFECT
Notice of effectiveness
13 Sep 22
CORRESP
Correspondence with SEC
8 Sep 22
UPLOAD
Letter from SEC
7 Sep 22
S-3
Shelf registration
1 Sep 22
424B3
Prospectus supplement
10 Aug 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
Latest ownership filings
4
Aaron I. Davis
3 May 24
144
Notice of proposed sale of securities
3 May 24
144
Notice of proposed sale of securities
2 May 24
144
Notice of proposed sale of securities
1 May 24
SC 13G/A
Southpoint Capital Advisors LP
8 Apr 24
4
Change in insider ownership
21 Feb 24
144
Notice of proposed sale of securities
21 Feb 24
SC 13G/A
Southpoint Capital Advisors LP
14 Feb 24
SC 13G/A
GILEAD SCIENCES, INC.
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Barbara Weber
8 Feb 24
4
Douglas Barry
8 Feb 24
4
Daniella Beckman
8 Feb 24
4
Adam Crystal
8 Feb 24
4
Daniella Beckman
5 Feb 24
4
Adam Crystal
5 Feb 24
4
Barbara Weber
5 Feb 24
4
Douglas Barry
5 Feb 24
3
Kanishka Pothula
14 Nov 23
4
Adam Crystal
2 Nov 23
SC 13D/A
BCTG Holdings, LLC
18 Oct 23
4/A
JOSEPH LEWIS
17 Oct 23
4
JOSEPH LEWIS
17 Oct 23
3
Initial statement of insider ownership
16 Oct 23
SC 13G/A
EcoR1 Capital, LLC
16 Oct 23
4
JOSEPH LEWIS
11 Oct 23
4/A
JOSEPH LEWIS
11 Oct 23
144
Notice of proposed sale of securities
10 Oct 23
144
Notice of proposed sale of securities
10 Oct 23
SC 13G
EcoR1 Capital, LLC
21 Sep 23
SC 13G/A
FMR LLC
11 Sep 23
4
John B Ketchum
31 Aug 23
3
John B Ketchum
31 Aug 23
3
Initial statement of insider ownership
22 Aug 23
SC 13G
Nextech Crossover I GP S.a r.l.
21 Aug 23
SC 13D/A
BCTG Holdings, LLC
16 Aug 23
4
JOSEPH LEWIS
15 Aug 23
4
Mace Rothenberg
8 Jun 23
4
Lesley Ann Calhoun
8 Jun 23
4
Alexis Borisy
8 Jun 23